Olema Pharmaceuticals, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- OLMAOlema Pharmaceuticals, Inc.0Calm
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Signing up patientsPhase 31,000 patientsMain results: Dec 2028 - OLMAOlema Pharmaceuticals, Inc.0Calm
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Running, no new patientsPhase 3510 patientsMain results: Oct 31, 2026 - OLMAOlema Pharmaceuticals, Inc.0Calm
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
FinishedPhase 1/2153 patientsMain results: Jul 30, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
2 sales (2 not pre-planned) · 0 purchases
- Harmon CyrusBoard member · Jul 24, 2026Sold 12,500 sharesabout $146 thousand · not pre-planned
- Harmon CyrusBoard member · Jul 23, 2026Sold 12,500 sharesabout $145 thousand · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- An executive or board member joined or leftNews report (8-K)Oct 15, 2026
- An executive or board member joined or left; Shared information with investorsNews report (8-K)Aug 13, 2026
- Quarterly reportQuarterly report (10-Q)Aug 10, 2026
- Shared quarterly resultsNews report (8-K)Aug 10, 2026
- News reportNews report (8-K)Jun 23, 2026